Meeting NewsVideo

VIDEO: Novel oral therapy drug safe, effective for wet AMD

SAN FRANCISCO —Twice daily dosing of oral AKST4290 over the course of 6 weeks improved visual acuity in patients with neovascular age-related macular degeneration, according to a presenter at the American Academy of Ophthalmology annual meeting.

“Further development of the drug is being planned [in] a randomized phase 2b study,” Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, told Ocular Surgery News. “Subsequently, a phase 3 trial and discussions are underway for trials with diabetic macular edema and edema due to retinal vein inclusions.” – by Alaina Tedesco

Reference: Stewart MW. Visual outcomes in two open-label trials of oral AKST4290 in naïve and refractory nAMD. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Stewart reports being a consultant for Alkahest and Bayer Pharmaceuticals and receiving institutional research support from Allergan and Regeneron.

SAN FRANCISCO —Twice daily dosing of oral AKST4290 over the course of 6 weeks improved visual acuity in patients with neovascular age-related macular degeneration, according to a presenter at the American Academy of Ophthalmology annual meeting.

“Further development of the drug is being planned [in] a randomized phase 2b study,” Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, told Ocular Surgery News. “Subsequently, a phase 3 trial and discussions are underway for trials with diabetic macular edema and edema due to retinal vein inclusions.” – by Alaina Tedesco

Reference: Stewart MW. Visual outcomes in two open-label trials of oral AKST4290 in naïve and refractory nAMD. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Stewart reports being a consultant for Alkahest and Bayer Pharmaceuticals and receiving institutional research support from Allergan and Regeneron.

    See more from Discoveries from AAO: AMD